AZD4205 in Peripheral T Cell Lymphoma Following First-Line Therapy (JACKPOT26)

NCT06511869 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
48
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Dizal Pharmaceuticals